Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 130 (RN7SKP130) is classified as a pseudogene, meaning it is a non-functional segment of DNA related to the functional RN7SK gene, which encodes the 7SK small nuclear RNA. The canonical RN7SK gene is a highly conserved, non-coding RNA transcribed by RNA polymerase III that forms a ribonucleoprotein complex (7SK snRNP) and serves as a global regulator of RNA polymerase II transcription elongation by sequestering positive transcription elongation factor b (P-TEFb)[4][6]. The RN7SK pseudogenes, including RN7SKP130, arise through retrotransposition or duplication events and lack evidence for functional RNA or protein products[3]. Pseudogenes like RN7SKP130 are not known to be involved in cellular processes, disease mechanisms, or as targets for therapeutic drugs. Structured and authoritative gene resources do not associate RN7SK pseudogene 130 with any protein, regulatory function, disease process, or therapeutic class[5]. If information about RN7SKP130 is sought as a "receptor", "enzyme", or regulatory target, this is "incorrect"—it is a pseudogene and does not fulfill such roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SK small nuclear pseudogene 130 (RN7SKP130).